FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly neurology and ophthalmology, and aims at early (preclinical) diagnosis of Parkinson's disease. Activity of alpha2-macroglobulin (α2-MG) is measured in the tear of each eye. If its value is more than 22 nmol/min*ml in one of the eyes and asymmetry of values of this value between paired eyes is more than 10 nmol/min*ml PD is diagnosed.
EFFECT: use of the invention enables the timely onset of PD treatment and monitoring the effectiveness of the therapy.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETECTING AN ACTIVE DESTRUCTIVE PROCESS IN THE RETINA IN AN EXPERIMENT | 2021 |
|
RU2768588C1 |
| METHOD FOR EARLY PRECLINICAL DIAGNOSTICS OF PARKINSON'S DISEASE BY CONCENTRATION OF CATECHOLAMINES IN PATIENT'S LACRIMAL FLUID | 2019 |
|
RU2775261C2 |
| METHOD FOR DETERMINING INDICATIONS FOR ACTIVE ANTI-INFLAMMATORY THERAPY BEFORE PERFORMING OPTO-RECONSTRUCTIVE OPERATIONS IN CHILDREN WITH ENDOGENOUS UVEITIS | 2022 |
|
RU2782132C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF AGE AND COMPLICATED CATARACT | 2017 |
|
RU2690152C2 |
| METHOD OF EXPERIMENTAL TREATMENT OF EYE NEURODEGENERATIVE PROCESS | 2023 |
|
RU2794835C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF FUS-ASSOCIATED NEURODEGENERATIVE DISORDERS IN MICE | 2021 |
|
RU2755768C1 |
| METHOD OF EARLY DIAGNOSIS OF FAMILIAL EXUDATIVE RETINOPATHY IN CHILDREN | 2022 |
|
RU2796894C1 |
| PHARMACEUTICAL COMPOSITION BASED ON ALPHA-METHYL-P-TYROSINE AND A METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2719575C1 |
| EARLY DIAGNOSTIC TECHNIQUE FOR PRIMARY OPEN-ANGLE GLAUCOMA AND PRE-GLAUCOMA | 2012 |
|
RU2513476C1 |
| METHOD FOR PRECLINICAL DIAGNOSTICS OF PARKINSON'S DISEASE IN PRACTICALLY HEALTHY PERSONS | 2006 |
|
RU2318437C1 |
